Abstract
Rising population density and global mobility are among the reasons why pathogens such as SARS-CoV-2, the virus that causes COVID-19, spread so rapidly across the globe. The policy response to such pandemics will always have to include accurate monitoring of the spread, as this provides one of the few alternatives to total lockdown. However, COVID-19 diagnosis is currently performed almost exclusively by Reverse Transcription Polymerase Chain Reaction (RT-PCR). Although this is efficient, automatable and acceptably cheap, reliance on one type of technology comes with serious caveats, as illustrated by recurring reagent and test shortages. We therefore developed an alternative diagnostic test that detects proteolytically digested SARS-CoV-2 proteins using Mass Spectrometry (MS). We established the Cov-MS consortium, consisting of fifteen academic labs and several industrial partners to increase applicability, accessibility, sensitivity and robustness of this kind of SARS-CoV-2 detection. This in turn gave rise to the Cov-MS Digital Incubator that allows other labs to join the effort, navigate and share their optimizations, and translate the assay into their clinic. As this test relies on viral proteins instead of RNA, it provides an orthogonal and complementary approach to RT-PCR, using other reagents that are relatively inexpensive and widely available, as well as orthogonally skilled personnel and different instruments. Data are available via ProteomeXchange with identifier PXD022550.
Competing Interest Statement
Van Oudenhove L., Claereboudt J., Oehrle S. Tanna, N and Vissers J.P.C.. are employed by Waters Corporation. Lane C.S., El Ouadi S., Vincendet JB., and Morrice N are employed by Sciex. Sigloch F. and Bhangu-Uhlmann A. are employed by Polyquant GmbH.
Funding Statement
This research was funded by BOF COVI-19 project grant (01C01920) from Ghent University; grants from the Research Foundation Flanders (FWO): B.V.P (grant number 11B4518N), R.G. (grant number 1S50918N), T.V.D.B (grant number 1S90918N), P.R, L.M (grant number G032816N), L.M. (grant number G042518N), N.D. (1S21017N), and M.D. (12E9716N); and by the European Unions Horizon 2020 Programme under Grant Agreement 823839 (H2020-INFRAIA-2018-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval: Obtained from University Hospital Leuven Ethics Committee with number S63879.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The LC-MS data generated within the Cov-MS consortium is shared and browsable through Panorama Public (https://panoramaweb.org/CovMS.url) and DDA, predicted and chromatogram libraries as well as the narrow window DIA data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (24) with the dataset identifier PXD022550 and 10.6019/PXD022550.
